Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial

Mayo Clinic Proceedings

Volumn 83, Issue 7, 2008, Pages 758-764

  Becker, David J ^a,d   Gordon, Ram Y ^a   Morris, Patti B ^a   Yorko, Jacqueline ^a   Gordon, Y Jerold ^b,c   Li, Mingyao ^c   Iqbal, Nayyar ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RES Q; SIMVASTATIN; TRIACYLGLYCEROL; XUEZHIKANG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 46749098263     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.7.758     Document Type: Article

References (45)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
2. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006 Dec 19;114(25):2788-2797. Epub 2006 Dec 11.
3. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18):1458-1462.
4. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164(4):208-211.
5. Braunstein JB, Cheng A, Cohn G, Aggarwal M, Nass CM, Blumenthal RS. Lipid disorders: justification of methods and goals of treatment. Chest. 2001;120(3):979-988.
6. Dalen JE. "Conventional" and "unconventional" medicine: can they be integrated [editorial]? Arch Intern Med. 1998;158(20):2179-2181.
7. Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med. 2001;135(4):262-268.
8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
9. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004 May 27;343:1-19.
10. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. 2006;295(19):2262-2269.
11. Knox J, Gaster B. Dietary supplements for the prevention and treatment of coronary artery disease. J Altern Complement Med. 2007;13(1):83-95.
12. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003;290(6):765-772.
13. Praca JM, Thomaz A, Caramelli B. Eggplant (Solanum melongena) extract does not alter serum lipid levels. Arq Bras Cardiol. 2004 Mar;82(3):269-276. Epub 2004 Apr 5.
14. Caron MF, White CM. Evaluation of the antihyperlipidemic properties of dietary supplements. Pharmacotherapy. 2001;21(4):481-487.
15. Ulbricht C, Basch E, Szapary P, et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med. 2005 Dec;13(4):279-290. Epub 2005 Sep 23.
16. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74(7):667-673.
17. Marchioli R, Barzi F, Bomba E, et al, GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897-1903.
18. Lee JH, O'Keefe JH, Lavie CJ, Marchioli R, Harris WS. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324-332.
19. Brouwer IA, Zock PL, Camm AJ, et al, SOFA Study Group. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA. 2006;295(22):2613-2619.
20. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007 Mar 19;99(6A)35C-43C. Epub 2006 Nov 28.
21. Harris WS. Expert opinion: omega-3 fatty acids and bleeding - cause for concern? Am J Cardiol. 2007 Mar 19;99(6A):44C-46C. Epub 2006 Nov 29.
22. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17(4):387-393.
23. Tuomilehto J, Lindström J, Eriksson JG, et al, Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350.
24. Trichopoulou A, Orfanos P, Norat T, et al. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. BMJ. 2005 Apr 30;330:991. Epub 2005 Apr 8.
25. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779-785.
26. Gielen S, Schuler G, Hambrecht R. Exercise training in coronary artery disease and coronary vasomotion. Circulation. 2001;103(1):E1-E6.
27. Himeno E, Nishino K, Okazaki T, Nanri H, Ikeda M. A weight reduction and weight maintenance program with long-lasting improvement in left ventricular mass and blood pressure. Am J Hypertens. 1999;12(7):682-690.
28. Sartorio A, Lafortuna CL, Marinone PG, Tavani A, La Vecchia C, Bosetti C. Short-term effects of two integrated, non-pharmacological body weight reduction programs on coronary heart disease risk factors in young obese patients. Diabetes Nutr Metab. 2003;16(4):262-265.
29. Sarafidis PA, Kanaki AI, Lasaridis AN. Statins and blood pressure: is there an effect or not? J Clin Hypertens (Greenwich). 2007;9(6):460-467.
30. Schiff HB, MacSearraigh ET, Kallmeyer JC. Myoglobinuria, rhabdomyolysis and marathon running. Q J Med. 1978;47(188):463-472.
31. Thompson PD, Gadaleta PA, Yurgalevitch S, Cullinane E, Herbert PN. Effects of exercise and lovastatin on serum creatine kinase activity. Metabolism. 1991;40(12):1333-1336.
32. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46(10):1206-1210.
33. Lefevre M, Champagne CM, Tulley RT, Rood JC, Most MM. Individual variability in cardiovascular disease risk factor responses to low-fat and low-saturated-fat diets in men: body mass index, adiposity, and insulin resistance predict changes in LDL cholesterol. Am J Clin Nutr. 2005;82(5):957-963.
34. Berglund L, Oliver EH, Fontanez N, et al. HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects. Am J Clin Nutr. 1999;70(6):992-1000.
35. Hsia SH, Pan D, Berookim P, Lee ML. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol. 2006 Oct 15;98(8):1047-1052. Epub 2006 Aug 28.
36. Frontini MG, Srinivasan SR, Xu JH, Tang R, Bond MG, Berenson G. Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study). Am J Cardiol. 2007 Jul 1;100(1):64-68. Epub 2007 May 11.
37. Real JT, Chaves FJ, Martínez-Usó I, García- García AB, Ascaso JF, Carmena R. Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur Heart J. 2001;22(6):465-471.
38. Schmidt-Trucksäss. Effects of exercise on plasma lipoproteins [letter]. N Engl J Med. 2003;348(15):1494-1496.
39. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347(19):1483-1492.
40. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43-53.
41. Moore RJ. Letter to Sonia Rodriguez, Mason Viamins. May 5, 2001. US Department of Health and Human Services Web site. http://www.fda.gov/ohrms/ dockets/dailys/01/Jun01/061101/let0494.pdf. Accessed May 20, 2008.
42. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. 2001;7(2):133-139.
43. Corsini A, Ferri N, Cortellaro M. Are pleiotropic effects of statins real? Vasc Health Risk Manag. 2007;3(5):611-613.
44. Davignon J. Cardioprotective and other emerging effects of statins. Int J Clin Pract Suppl. 2004 Oct;143:49-57.
45. Kastelein JJ, Akdim F, Stroes ES, et al, ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008 Apr 3;358(14):1431-1443. Epub 2008 Mar 30.